The company, which makes medical technology for
diabetes patients, filed to go public with the Securities and Exchange
Commission on Friday. It did not say how many shares it would offer or
at what price.
- Medtronic will own at least 80.1% of the voting stock for MiniMed once the IPO is complete
The Medtronic Diabetes business (MiniMed) quarterly performance
Medtronic reported $721 million in revenue for the Diabetes business, growing 11.5% on a reported basis.
The company’s MiniMed 780G automated insulin delivery system and Simplera Sync sensor drove growth in international markets.
The company expects accelerated performance with the launch of Simplera Sync, plus the Instinct sensor developed in collaboration with Abbott. Martha said this partnership brings Abbott’s most advanced continuous glucose monitor (CGM) platform to Medtronic customers.
Medtronic reported $721 million in revenue for the Diabetes business, growing 11.5% on a reported basis.
The company’s MiniMed 780G automated insulin delivery system and Simplera Sync sensor drove growth in international markets.
The company expects accelerated performance with the launch of Simplera Sync, plus the Instinct sensor developed in collaboration with Abbott. Martha said this partnership brings Abbott’s most advanced continuous glucose monitor (CGM) platform to Medtronic customers.
The MiniMed™ 780G system automatically adjusts insulin delivery and corrects glucose levels every 5 minutes 24/7, requiring no finger pricks.
No comments:
Post a Comment